Respiratory medicine最新文献

{"title":"High-flow nasal cannula versus CPAP for the prevention of bronchopulmonary dysplasia in preterm infants: a systematic review with meta-analysis and trial sequential analysis","authors":"Janneth Milena Avendaño-Vanegas ,&nbsp;Henry Mauricio Parada-Gereda ,&nbsp;Luis Alexander Peña-López ,&nbsp;Leonardo Arzayus-Patiño","doi":"10.1016/j.rmed.2026.108651","DOIUrl":"10.1016/j.rmed.2026.108651","url":null,"abstract":"<div><h3>Background</h3><div>Bronchopulmonary dysplasia (BPD) is common in preterm infants and is associated with invasive ventilation and prolonged oxygen therapy. Continuous positive airway pressure (CPAP) has been the standard non-invasive respiratory support for decades, but it may cause nasal trauma and poor tolerance. High-flow nasal cannula (HFNC) could improve comfort; however, its effectiveness in preventing BPD remains unconfirmed, and the available evidence is heterogeneous.</div></div><div><h3>Methods</h3><div>We conducted a systematic review and meta-analysis with trial sequential analysis (TSA) of randomised controlled trials comparing HFNC with CPAP for the prevention of BPD in preterm infants. Searches were performed in PubMed, Scopus, Cochrane Library, LILACS, and Science Direct up to June 2025, with no language restrictions. The primary outcome was the incidence of BPD; secondary outcomes included air leak and nasal injury. Methodological quality was assessed using the Cochrane RoB 2.0 tool, certainty of evidence with GRADE, and publication bias with funnel plots and Egger's and Begg's tests. The protocol was registered in PROSPERO (CRD420251076520).</div></div><div><h3>Results</h3><div>Twenty trials were included (n = 2871 preterm infants). No significant differences were found in the incidence of BPD between HFNC and CPAP (RR: 0.86; 95 % CI: 0.73–1.02; p = 0.08; I² = 0 %). Similarly, no differences were observed for air leak (RR: 0.76; 95 % CI: 0.45–1.27; p = 0.29). However, HFNC significantly reduced the risk of nasal injury (RR: 0.40; 95 % CI: 0.33–0.49; p &lt; 0.00001). TSA indicated insufficient evidence to confirm a 20 % reduction in BPD. Most studies were at low risk of bias; certainty of the evidence was rated as low for BPD and air leak, and high for nasal injury.</div></div><div><h3>Conclusions</h3><div>HFNC showed no significant differences compared with CPAP in preventing BPD or air leak in preterm infants, although it reduced the risk of nasal injury. TSA suggests that current evidence is insufficient to confirm or refute a 20 % relative risk reduction in BPD, highlighting the need for further high-quality trials to establish definitive conclusions.</div></div>","PeriodicalId":21057,"journal":{"name":"Respiratory medicine","volume":"252 ","pages":"Article 108651"},"PeriodicalIF":3.1,"publicationDate":"2026-01-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146023214","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cone beam CT with integration improves diagnostic yield of bronchoscopic peripheral pulmonary lesion biopsies","authors":"Bryan S. Benn ,&nbsp;James Dugan ,&nbsp;Christian F. Cuvillier Padilla ,&nbsp;Yifan Wang ,&nbsp;Xiaofeng Wang ,&nbsp;See-Wei Low","doi":"10.1016/j.rmed.2026.108666","DOIUrl":"10.1016/j.rmed.2026.108666","url":null,"abstract":"<div><h3>Background</h3><div>Robotic bronchoscopy has improved the ability to biopsy peripheral pulmonary lesions (PPL). Intra-procedure PPL, biopsy tool, and catheter visualization represents another means towards refining procedural outcomes. Recently, the ability to integrate this information in real-time became available through 3D mobile cone beam CT (CBCT) imaging. We analyzed the impact of imaging integration on diagnostic yield of shape sensing robotic assisted bronchoscopy (ssRAB) biopsies compared to procedures done without integration.</div></div><div><h3>Methods</h3><div>Patients undergoing ssRAB (Ion Endoluminal System) with 2D fluoroscopy (03/2023–03/2024) and with 3D CBCT with integration (Cios system) (04/2024–01/2025) were retrospectively identified. The primary outcome was diagnostic yield. Secondary outcomes included diagnostic accuracy and procedural complications.</div></div><div><h3>Results</h3><div>71 PPLs (67 patients) underwent ssRAB without integration and 102 PPLs (95 patients) were biopsied with integration. While demographics were similar, PPLs in the integration group were smaller (2.11 ± 1.26 cm vs 2.46 ± 1.19 cm, p = 0.010) and more frequently located in the peripheral lung third (n = 82 (80.4 %) vs n = 41 (57.7 %), p = 0.003).</div><div>Diagnostic yield without integration was 72 % (51/71) and with integration was 86 % (88/102) (p = 0.019). Diagnostic accuracy without integration was 78 % (55/71) and with integration was 89 % (91/102) (p = 0.036).</div><div>After controlling for other variables, biopsies with integration had a significantly higher diagnostic yield compared to those without integration (OR = 3.34, 95 % CI 1.39–8.44, p = 0.008). Pneumothorax rate (3 without integration vs 1 with integration, p = 0.3) was similar.</div></div><div><h3>Interpretation</h3><div>The use of 3D CBCT for real time integration of PPL location and biopsy tool and catheter relationship improves diagnostic yield of bronchoscopic biopsies performed via ssRAB.</div></div>","PeriodicalId":21057,"journal":{"name":"Respiratory medicine","volume":"252 ","pages":"Article 108666"},"PeriodicalIF":3.1,"publicationDate":"2026-01-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146023210","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"PA/A ratio >1 detected by CT-scan during acute exacerbation of chronic obstructive pulmonary disease: A novel prognostic factor for long-term mortality based on a cohort study","authors":"Chen Zhou ,&nbsp;Jing Liu ,&nbsp;Qun Yi ,&nbsp;Jiaxin Zeng ,&nbsp;Xueqing Chen ,&nbsp;Xuelian Li ,&nbsp;Liqing Peng ,&nbsp;Haixia Zhou","doi":"10.1016/j.rmed.2026.108665","DOIUrl":"10.1016/j.rmed.2026.108665","url":null,"abstract":"<div><h3>Background</h3><div>The pulmonary artery (PA) to aorta (A) (PA/A) ratio is a prognostic factor of many diseases, but the long-term prognostic value of PA/A during acute exacerbation of chronic obstructive pulmonary disease (AECOPD) has never been disclosed.</div></div><div><h3>Aim</h3><div>To investigate the long-term prognostic value of PA/A detected by CT-scan during AE stage of COPD inpatients.</div></div><div><h3>Design</h3><div>A non-interventional cohort study.</div></div><div><h3>Methods</h3><div>Patients surviving from AECOPD were prospectively enrolled from West China Hospital between September 2017 and July 2021 and followed-up till the fifth year after discharge. PA and A diameters were measured based on CT-scan during hospitalization. LASSO-COX analysis was used to identify the independent prognostic factors. Stratified analysis by sex, age groups were performed.</div></div><div><h3>Results</h3><div>Among the 1466 patients involved, 402 (27.4 %) died during follow-up (median follow-up time: 41.0 months). Multivariate LASSO-COX analysis showed that PA/A &gt;1 during exacerbation period was associated with increased long-term mortality risk [HR = 1.498, 95 % CI (1.120–2.004), P = 0.007], especially in male and old subgroups. With the rise of PA/A ratio, mortality rate showed a significant upward trend. Kaplan–Meier analysis showed patients with PA/A &gt;1 had significantly lower survival rate. After exacerbation, PA/A ratio showed a significant reduction in patients with PA/A ≤1 (exacerbation vs. stable stage: 0.79 ± 0.11 vs. 0.76 ± 0.11, P &lt; 0.001), while that remained stagnant in patients with PA/A &gt;1 (1.13 ± 0.12 vs. 1.13 ± 0.16, P = 0.592).</div></div><div><h3>Conclusion</h3><div>PA/A ratio &gt;1 detected during AE stage was a steady and effective prognostic factor of long-term mortality in COPD patients. Further multicenter is warranted to validate the association.</div></div>","PeriodicalId":21057,"journal":{"name":"Respiratory medicine","volume":"252 ","pages":"Article 108665"},"PeriodicalIF":3.1,"publicationDate":"2026-01-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146023211","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy of high-flow nasal cannula versus conventional oxygen therapy in high-risk patients undergoing bronchoscopy: a meta-analysis of RCTs.","authors":"Weizhong Wang, Pan Zhang, Ting Xu, Haiying Guo, Shanshan Zhu, Xiaoyan Yao","doi":"10.1016/j.rmed.2026.108664","DOIUrl":"https://doi.org/10.1016/j.rmed.2026.108664","url":null,"abstract":"<p><strong>Background: </strong>Patients with underlying conditions such as chronic obstructive pulmonary disease (COPD) or obesity are at high risk for hypoxemia during bronchoscopy. Whether a high-flow nasal cannula (HFNC) is superior to conventional oxygen therapy (COT) for preventing this complication is well-studied, but a focused synthesis in high-risk populations is needed.</p><p><strong>Objectives: </strong>To compare the efficacy of HFNC versus COT in preventing intraprocedural hypoxemia and other complications in high-risk patients undergoing bronchoscopy.</p><p><strong>Methods: </strong>We systematically searched PubMed, Embase, Cochrane Library, and Web of Science for RCTs up to October 2025. Methodological quality was assessed using the Cochrane Risk of Bias tool, and data were pooled with RevMan 5.3.</p><p><strong>Results: </strong>Five RCTs (1054 patients) were included. Compared to COT, HFNC significantly reduced oxygen desaturation (OR 0.14, 95% CI 0.08-0.27; P < 0.00001; I² = 62%) and procedure interruptions (OR 0.18, 95% CI 0.09-0.34; P < 0.00001; I² = 21%). HFNC also increased the lowest SpO₂ (MD = 5.89%, 95% CI 3.19-8.58; P < 0.0001; I² = 90%). No significant difference was found in procedure duration. Sensitivity analyses confirmed the robustness of the primary findings, and the certainty of evidence was moderate for most outcomes.</p><p><strong>Discussion: </strong>HFNC significantly reduces the risk of hypoxemia and procedure interruptions compared with COT in high-risk patients undergoing bronchoscopy, supporting its use to improve procedural safety in this vulnerable population. Limitations include heterogeneity partly attributable to varying hypoxemia definitions and an inability to blind personnel.</p><p><strong>Registration: </strong>PROSPERO CRD420251174924.</p>","PeriodicalId":21057,"journal":{"name":"Respiratory medicine","volume":" ","pages":"108664"},"PeriodicalIF":3.1,"publicationDate":"2026-01-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146030713","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of carbon footprint information on inhaler prescribing intentions by general practitioners: protocol for an online factorial randomised experiment","authors":"Luise Kazda ,&nbsp;Timothy E. Schlub ,&nbsp;Michelle Guppy ,&nbsp;Mike Forrester ,&nbsp;Debbie Rigby ,&nbsp;Alexandra Barratt ,&nbsp;Darlene Cox ,&nbsp;Michael J. Loftus ,&nbsp;Katy Bell","doi":"10.1016/j.rmed.2026.108657","DOIUrl":"10.1016/j.rmed.2026.108657","url":null,"abstract":"<div><h3>Background</h3><div>Many asthma patients experience suboptimal disease control and are disproportionally impacted by worsening environmental risk factors due to climate change. General practitioners (GPs) are well-placed and trusted to lead conversations to improve asthma management. The resulting treatment improvements have the potential to simultaneously reduce the significant greenhouse gas emissions from inhalers as a co-benefit.</div></div><div><h3>Objectives</h3><div>This study aims to explore whether adding environmental impact information for respiratory inhalers can influence clinician prescribing while improving quality of care and investigates optimal ways to communicate environmental impacts to GPs.</div></div><div><h3>Methods</h3><div>We will conduct a factorial (2 × 2 plus control) randomised online hypothetical experiment with Australian GPs. Following consent and baseline information on guideline-concordant maintenance-and-reliever-therapy (“MART”) prescribing, participants will be randomised 1:1:1:1:1 to five conditions: A. Emissions impact: collective action/with graphic; B. Emissions impact: single-action/with graphic; C. Emissions impact: collective action/no graphic; D. Emission impact: single-action/no graphic; E. Control: no further information. The required sample size is 250 GPs. The primary outcome is participant choice of inhaler type (binary choice of dry powder or pressurised metered dose). Secondary outcomes include participant level of confidence in their choice, management choice anxiety, acceptability and trustworthiness of information received (all measured on Likert scales) and reasons for inhaler choice (free text). Study duration will be less than 10 min. We will use t-tests and chi-squared tests for univariable analysis of continuous and binary outcomes respectively, and t, F or likelihood ratio tests for regression models as appropriate.</div></div><div><h3>Results</h3><div>Not applicable – this is a study protocol.</div></div><div><h3>Conclusion</h3><div>This study will provide evidence on whether and how environmental impact information can influence prescribing intentions among GPs. Findings will inform future interventions aimed at aligning clinical and environmental goals in respiratory care.</div></div>","PeriodicalId":21057,"journal":{"name":"Respiratory medicine","volume":"252 ","pages":"Article 108657"},"PeriodicalIF":3.1,"publicationDate":"2026-01-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146019588","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Beyond corticosteroids: A systematic review and meta-analysis of novel therapies for hypersensitivity pneumonitis","authors":"Omnia Azmy Nabeh ,&nbsp;Youssef Mohamed Amin Soliman ,&nbsp;Reem Ibrahim Elkorashy ,&nbsp;Yosri Akl ,&nbsp;Emad Elkholy ,&nbsp;Mennatullah Abdelhaleem Ahmed Mohamed Hassan ,&nbsp;Fatma Elzahraa Ahmed Abd elaleem ,&nbsp;Rana kamal El Said Gabr ,&nbsp;Katarzyna B. Lewandowska ,&nbsp;Soha Aly Elmorsy","doi":"10.1016/j.rmed.2026.108661","DOIUrl":"10.1016/j.rmed.2026.108661","url":null,"abstract":"<div><h3>Introduction</h3><div>Hypersensitivity pneumonitis (HP) is a complex immune-mediated interstitial lung disease triggered by inhaled antigens. While corticosteroids remain the mainstay of therapy, their benefit is limited in fibrotic HP. Several novel agents—including pirfenidone, nintedanib, rituximab, azathioprine, mycophenolate mofetil (MMF), leflunomide, and roflumilast—have been investigated as alternatives.</div></div><div><h3>Methods</h3><div>This meta-analysis followed PRISMA guidelines and was registered on PROSPERO (CRD42023428070). Eligible studies included clinical and non-clinical trials assessing both traditional and novel therapies in HP. Primary outcomes were mean difference from baseline (MDB) and percentage change from baseline (PCB) in forced vital capacity (FVC%) and diffusing capacity for carbon monoxide (DLCO%). Meta-analyses were performed using fixed- and random-effects models, with heterogeneity assessed via I². Sensitivity analyses and publication bias assessments were also conducted. Risk of bias was evaluated using CASP and RoB-2 tools.</div></div><div><h3>Results</h3><div>Twenty-three studies comprising 975 patients (aged 39.3–83 years) were included. Rituximab, azathioprine, MMF, and corticosteroids showed non-significant pooled MDBs in FVC%, with MDB of −0.87 %, 2.49 %,1.96 %, and 2.03 %, respectively. For DLCO%, rituximab and MMF showed positive effects, with a MDB of 6.69 and 5.98, respectively, while azathioprine had minimal impact. Single-study analyses suggested that pirfenidone and nintedanib may stabilize lung function; their combination improved DLCO% but not FVC%. Leflunomide and roflumilast demonstrated promising effects in single reports.</div></div><div><h3>Conclusion</h3><div>Due to heterogeneity and limited high-quality evidence, definitive conclusions about novel therapies in HP remain elusive. However, rituximab and MMF showed promising results. Long-term randomized trials with standardized endpoints are needed to guide therapeutic decisions.</div></div>","PeriodicalId":21057,"journal":{"name":"Respiratory medicine","volume":"252 ","pages":"Article 108661"},"PeriodicalIF":3.1,"publicationDate":"2026-01-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146003828","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Under the surface: Unveiling the respiratory health crisis among mussel pickers in Kozhikode district, Southern India.","authors":"Binub K, Dhananjayan V, Madayil D, Akshaya K, Ravichandran B, Thamaraikannan M, Panjakumar K, Mala A, M Jaseer","doi":"10.1016/j.rmed.2026.108653","DOIUrl":"10.1016/j.rmed.2026.108653","url":null,"abstract":"<p><p>Occupational respiratory diseases pose a considerable health challenge in various industries, especially within the global seafood processing sector. The intricate interactions between lifestyle, pre-existing medical disorders and occupational exposures pose a serious threat to respiratory health. This cross-sectional study explores the respiratory health crisis among mussel workers in Kozhikode District, Southern India. The study aimed to quantify lung function morbidity and the prevalence of respiratory illnesses in this population. Pulmonary function test revealed key finding, including a concerning prevalence of respiratory impairment among mussel workers (21.5 %). Cough with phlegm (14 %), sinusitis (11.8 %), wheezing (4.3 %), shortness of breath (4.3 %), epistaxis (6.5 %), and most significantly, hemoptysis (3 %), other symptoms vertigo (7.53 %) and ophthalmic complaints (4.3 %) were observed. Significant correlations between lung health and variables such as alcohol consumption, history of tuberculosis, smoking, adherence to personal protective equipment (PPE) were determined. The occupational practice of marine mussel harvesting through breath-hold free-diving imposes significant pulmonary risk. Our findings demonstrate that mussel pickers develop a mixed obstructive and restrictive pulmonary impairment. This pathology may be driven by the synergistic effects of repetitive mechanical lung injury.</p>","PeriodicalId":21057,"journal":{"name":"Respiratory medicine","volume":" ","pages":"108653"},"PeriodicalIF":3.1,"publicationDate":"2026-01-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146003250","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Corrigendum to \"Association of circadian syndrome and lung health: A population-based cohort study\" [Respir. Med. 240 (2025) 108031].","authors":"Shuwen Zhang, Jiangtao Lin","doi":"10.1016/j.rmed.2026.108645","DOIUrl":"https://doi.org/10.1016/j.rmed.2026.108645","url":null,"abstract":"","PeriodicalId":21057,"journal":{"name":"Respiratory medicine","volume":" ","pages":"108645"},"PeriodicalIF":3.1,"publicationDate":"2026-01-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145998994","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prognosis of patients with bronchiectasis receiving long-term oxygen therapy","authors":"Kazuki Ono ,&nbsp;Masashi Ito ,&nbsp;Risako Harada ,&nbsp;Takashi Ohe ,&nbsp;Koji Furuuchi ,&nbsp;Keiji Fujiwara ,&nbsp;Tatsuya Kodama ,&nbsp;Mitsuru Tabusadani ,&nbsp;Kozo Morimoto","doi":"10.1016/j.rmed.2026.108655","DOIUrl":"10.1016/j.rmed.2026.108655","url":null,"abstract":"<div><h3>Objectives</h3><div>Long-term oxygen therapy (LTOT) for bronchiectasis is recommended using the same eligibility criteria as for chronic obstructive pulmonary disease (COPD); however, the evidence supporting LTOT in bronchiectasis is limited, and no studies have evaluated the prognosis of the disease in these patients. The aim of the present study was to investigate the characteristics and prognosis of bronchiectasis in patients receiving LTOT.</div></div><div><h3>Methods</h3><div>This retrospective cohort study included patients with bronchiectasis and COPD who started LTOT between April 2011 and September 2022. Patients with interstitial lung disease (ILD) who started LTOT after June 2020 while receiving antifibrotic therapy were also included. We compared baseline characteristics and survival times among patients with bronchiectasis, COPD, and ILD. Furthermore, among patients with bronchiectasis, we compared these parameters between those with nontuberculous mycobacteria (NTM) culture-positive and NTM culture-negative results.</div></div><div><h3>Results</h3><div>A total of 93 consecutive patients with bronchiectasis were newly initiated on LTOT. Compared with patients with COPD and ILD, those with bronchiectasis had a significantly lower BMI, %FVC and %FEV. Survival was significantly shorter in patients with bronchiectasis (664 [372–1078] days) than in those with COPD (1008 [590–1722] days), whereas no significant difference was observed compared to ILD (669 [208–989] days). Patients who were NTM culture-positive (405 [156–646] days) had a significantly shorter survival than those who were NTM culture-negative (946 [573–1380] days).</div></div><div><h3>Conclusions</h3><div>The prognosis of bronchiectasis in patients was extremely poor, worse than that of COPD and comparable to that of ILD.</div></div>","PeriodicalId":21057,"journal":{"name":"Respiratory medicine","volume":"252 ","pages":"Article 108655"},"PeriodicalIF":3.1,"publicationDate":"2026-01-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145999062","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"High PEEP in perioperative vs. hypoxemic respiratory failure: Lessons from recent trials","authors":"Lei Gu ,&nbsp;Jian Yue ,&nbsp;Yuxuan Chen ,&nbsp;Wei Liu ,&nbsp;Jing Lin","doi":"10.1016/j.rmed.2026.108659","DOIUrl":"10.1016/j.rmed.2026.108659","url":null,"abstract":"","PeriodicalId":21057,"journal":{"name":"Respiratory medicine","volume":"252 ","pages":"Article 108659"},"PeriodicalIF":3.1,"publicationDate":"2026-01-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145994491","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}